Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease

Reem Karmali, MDMSc, Jeremy S Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M Petrich, MD, Ephraim Hochberg, MD, Ronald Takvorian, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137695

Published: 2020

Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2019) 134 (Supplement_1): 3990.

https://doi.org/10.1182/blood-2019-126920

Published: 2019

Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2019) 134 (Supplement_1): 762.

https://doi.org/10.1182/blood-2019-122451

Published: 2019

Journal Articles

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

Jeremy S. Abramson, MD MMSc, Robert A. Redd, MS, Jeffrey A. Barnes, MD PhD, Elizabeth Bengtson, MD, Ronald W. Takvorian, MD, Lubomir Sokol, MD PhD, Frederick Lansigan, MD, Philippe Armand, MD PhD, Bijal D. Shah, MD, Eric D Jacobsen, MD, Donna S Neuberg, ScD, Ann S. LaCasce, MD MSc, Celeste M. Bello, MD

Blood (2018) 132 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2018-99-115173

Published: 2018

Journal Articles

Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy

Rajat Bannerji, MD PhD, Ranjana H. Advani, MD, Jennifer R. Brown, MD PhD, Jon E. Arnason, MD, Jeffrey A. Barnes, MD PhD, John N. Allan, MD, Stephen M Ansell, MD PhD, Susan M. O'Brien, MD, Julio C. Chavez, MD, Lieve Adriaens, PharmD, Melanie Ufkin, BS, PhD, Ana Kostic, PhD, Anne Josee Paccaly, PharmD, PhD, Bo Gao, PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Max S. Topp, MD

Blood (2017) 130 (Supplement 1): 1550.

https://doi.org/10.1182/blood.V130.Suppl_1.1550.1550

Published: 2017

Journal Articles

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Rajat Bannerji, MD PhD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jon Arnason, MD, Susan M. O'Brien, MD, John N. Allan, MD, Julio C. Chavez, MD, Jeffrey A. Barnes, MD PhD, Robin Joyce, MD, Stephen Ansell, MD PhD, Max S Topp, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ana Kostic, PhD, Anne Paccaly, PharmD, PhD, Bo Gao, PhD, Pamela A. Trail, PhD, Israel Lowy, MD PhD, Carrie Brownstein, MD

Blood (2016) 128 (22): 621.

https://doi.org/10.1182/blood.V128.22.621.621

Published: 2016

Journal Articles

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial

Jeremy S. Abramson, MD, Eric D. Jacobsen, MD, Robert Allyn Redd, MS, Tak Takvorian, MD, David C. Fisher, MD, Jennifer R. Brown, Joel H Schwartz, MD, James Weitzman, MD, Donna Neuberg, ScD, Jeffrey A. Barnes, MD PhD, Ephraim P Hochberg, MD

Blood (2014) 124 (21): 4423.

https://doi.org/10.1182/blood.V124.21.4423.4423

Published: 2014

Journal Articles

Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Jeffrey A. Barnes, MD PhD, Robert Allyn Redd, MS, Eric D. Jacobsen, MD, David C. Fisher, MD, Arnold S. Freedman, MD, Ephraim P Hochberg, MD, Tak Takvorian, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2014) 124 (21): 3055.

https://doi.org/10.1182/blood.V124.21.3055.3055

Published: 2014

Journal Articles

Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

Jeffrey A. Barnes, MD, PhD, Yang Feng, PhD, Ephraim P Hochberg, MD, Tak Takvorian, MD, James Weitzman, MD, David C. Fisher, MD, Eric D. Jacobsen, MD, Robin Joyce, MD, Donna S. Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2013) 122 (21): 3062.

https://doi.org/10.1182/blood.V122.21.3062.3062

Published: 2013

Journal Articles

Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy

Jeremy S. Abramson, MD, Jeffrey A. Barnes, MD, PhD, Yang Feng, PhD, Tak Takvorian, MD, Donna S. Neuberg, ScD, Ephraim P. Hochberg, MD, Aliyah R. Sohani, MD

Blood (2012) 120 (21): 1619.

https://doi.org/10.1182/blood.V120.21.1619.1619

Published: 2012

Journal Articles

Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma

Jeffrey A. Barnes, MD, PhD, Eric Jacobsen, MD, Yang Feng, PhD, Arnold S. Freedman, MD, Ephraim P. Hochberg, MD, Ann S. LaCasce, MD, Philippe Armand, MD, PhD, Robin Joyce, MD, Donna Neuberg, ScD, David C. Fisher, MD, Jeremy S. Abramson, MD

Blood (2011) 118 (21): 1635.

https://doi.org/10.1182/blood.V118.21.1635.1635

Published: 2011

Journal Articles

B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship

Anuj K. Mahindra, MD, Aliyah R. Sohani, MD, Christiana E. Toomey, James S. Michaelson, PhD, Jeffrey A. Barnes, MD, PhD, Jeremy S. Abramson, MD, Ronald Takvorian, MD, Noopur S. Raje, MD, Ephraim P. Hochberg, MD

Blood (2011) 118 (21): 1590.

https://doi.org/10.1182/blood.V118.21.1590.1590

Published: 2011

Journal Articles

High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP

Jeremy S. Abramson, MD, Matthew D Hellmann, MD, Yang Feng, PhD, Jeffrey A. Barnes, MD, PhD, Tak Takvorian, MD, Christiana E. Toomey, Michael Sheppard, James S. Michaelson, PhD, Donna Neuberg, ScD, Ephraim P. Hochberg, MD

Blood (2011) 118 (21): 1601.

https://doi.org/10.1182/blood.V118.21.1601.1601

Published: 2011

Journal Articles

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Jeffrey A. Barnes, MD, PhD, Kristen Stevenson, Ephraim P. Hochberg, MD, Tak Takvorian, MD, David C. Fisher, MD, Ann LaCasce, MD, Jennifer R. Brown, MD, PhD, Anuj K. Mahindra, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2011) 118 (21): 3716.

https://doi.org/10.1182/blood.V118.21.3716.3716

Published: 2011

Journal Articles

Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older

Christiana E. Toomey, Alona Muzikanksy, MA, Alfred Ian Lee, MD, PhD, Jeffrey A. Barnes, MD, PhD, James S. Michaelson, PhD, Jeremy S. Abramson, MD, Ephraim P. Hochberg, MD

Blood (2010) 116 (21): 733.

https://doi.org/10.1182/blood.V116.21.733.733

Published: 2010

Journal Articles

A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Jeremy S Abramson, MD, Tak Takvorian, MD, Eric D Jacobsen, MD, Jennifer R Brown, MD, PhD, Jeffrey A. Barnes, MD, PhD, Yang Feng, Donna Neuberg, ScD, Ephraim P. Hochberg, MD

Blood (2010) 116 (21): 1775.

https://doi.org/10.1182/blood.V116.21.1775.1775

Published: 2010

Journal Articles

Primary Pancreatic Lymphoma

Elisabeth S. Malin, Christiana E. Toomey, Jill Ono, MD, Aliyah R. Sohani, MD, James S. Michaelson, PhD, Jeffrey A. Barnes, MD, PhD, Jeremy S. Abramson, MD, Ephraim P. Hochberg, MD

Blood (2010) 116 (21): 4150.

https://doi.org/10.1182/blood.V116.21.4150.4150

Published: 2010

Journal Articles

Breast Implant Associated Anaplastic Large Cell Lymphoma Is More Frequent and Lethal Than Previously Reported

Matthew Carty, MD, Christiana E. Toomey, Evan Farkash, MD, PhD, James W. May, MD, James S. Michaelson, PhD, Jeffrey A. Barnes, MD, PhD, Jeremy S. Abramson, MD, Ephraim P. Hochberg, MD

Blood (2010) 116 (21): 4760.

https://doi.org/10.1182/blood.V116.21.4760.4760

Published: 2010

NARROW

Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial

Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy

Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma

B Cell Lymphoma In Association with Multiple Myeloma: Analysis of the Biologic Relationship

High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older

A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Primary Pancreatic Lymphoma

Breast Implant Associated Anaplastic Large Cell Lymphoma Is More Frequent and Lethal Than Previously Reported

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only